

Singapore approves GSK's Jemperli plus chemotherapy as first frontline immuno-oncology treatment

08 August 2024 | News

For dMMR/MSI-H primary advanced or recurrent endometrial cancer



GSK Singapore has announced that the Singapore Health Sciences Authority (HSA) has approved a new indication for *Jemperli* (dostarlimab), which may now be used in combination with carboplatin and paclitaxel, followed by *Jemperli* as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H).

With this approval, *Jemperli* is now indicated earlier in treatment, in combination with chemotherapy, for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer. *Jemperli* has earlier received approval from Singapore HSA as a monotherapy in adult patients with dMMR recurrent or advanced endometrial cancer that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.

Latest Singapore Cancer Registry, from 2017-2021, reported endometrial cancer as the fourth most common and had the ninth highest cancer mortality rate among females in the country, with 3,133 new cases diagnosed during the period. Approximately 15-20% of endometrial cancer patients globally and 28% in Singapore were at advanced disease stage at the time of diagnosis. An estimated 20-29% of all endometrial cancers globally are dMMR/MSI-H. Chemotherapy used alone has been the current standard of care for primary advanced or recurrent endometrial cancer, and many patients eventually experience disease progression.